Glass Allison S, Dall'Era Marc A
Department of Urology, University of California Davis Medical Center, Sacramento, CA, USA.
Transl Androl Urol. 2018 Apr;7(2):236-242. doi: 10.21037/tau.2018.02.08.
For men with lower risk prostate cancer, there is ever-growing literature that demonstrates the oncologic safety of deferring radical treatment and opting for regular monitoring for disease progression. This strategy's success is largely owed to appropriate, systematic monitoring protocols that typically employ various prostate specific antigen (PSA) metrics or digital rectal exam (DRE) findings. Novel biologic markers and advanced imaging techniques have shown promise in active surveillance (AS) populations such as for use of patient candidacy as well as detection of disease progression. This review summarizes contemporary surveillance protocols as well as the emerging technologies which demonstrate significant potential to improve such protocols.
对于低风险前列腺癌男性患者，越来越多的文献表明，推迟根治性治疗并选择定期监测疾病进展在肿瘤学上是安全的。这一策略的成功很大程度上归功于适当、系统的监测方案，这些方案通常采用各种前列腺特异性抗原（PSA）指标或直肠指检（DRE）结果。新型生物标志物和先进成像技术在主动监测（AS）人群中显示出前景，例如用于确定患者是否适合以及检测疾病进展。本综述总结了当代监测方案以及显示出显著潜力以改进此类方案的新兴技术。
